Systemic endothelial cell markers in primary antiphospholipid syndrome

Area of Science:

• Hematology
• Immunology
• Pathophysiology

Background:

• The prothrombotic mechanisms in Hughes' syndrome, or antiphospholipid syndrome (APS), remain unclear.
• Previous research suggests endothelial cell (EC) activation and procoagulant factor expression contribute to APS pathogenesis.
• In vitro studies show antiphospholipid antibodies (aPL) induce EC activation.

Purpose of the Study:

• To investigate in vivo evidence of endothelial cell perturbation in primary APS patients.
• To quantify soluble markers of EC dysfunction and platelet activation in APS.
• To explore the role of vascular endothelial growth factor (VEGF) and soluble tissue factor (sTF) in APS pathogenesis.

Main Methods:

• Serum and plasma samples were collected from primary APS patients and healthy controls.
• Enzyme-linked immunosorbent assays (ELISAs) were used to measure soluble markers: sVCAM, sICAM-1, IL-6, ET-1, vWF, sTF, p-selectin, and VEGF.
• Statistical analysis compared marker levels between patient and control groups.

Main Results:

• No significant differences were observed in sVCAM, sICAM-1, IL-6, ET-1, or vWF levels between APS patients and controls.
• Significantly higher levels of VEGF and sTF were detected in APS patients compared to controls (p <0.05).
• Soluble p-selectin levels were also measured as a marker of platelet activation.

Conclusions:

• Elevated plasma levels of soluble tissue factor (sTF) and vascular endothelial growth factor (VEGF) suggest a potential role in APS-associated thrombosis.
• The precise cellular origin of these elevated markers in APS requires further elucidation.
• These findings contribute to understanding the pathophysiology of antiphospholipid syndrome.